You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Search all journals

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Search results

Search results page

Articles (11)

Journals (0)

1-10 of 11 results for claudin 18.2

Sort by:

Relevance

Select all

Select all

Sort by:

Relevance

Select article: Expression of Claudin 18.2 and its Prognostic Significance in Patients with Japanese Gastric Solid-Type Poorly Differentiated Adenocarcinoma

Retricted access

Research article

First published 2026

Expression of Claudin 18.2 and its Prognostic Significance in Patients with Japanese Gastric Solid-Type Poorly Differentiated Adenocarcinoma

Shinya Umekita, Daisuke Kiyozawa, Shinichiro Kawatoko [...]

International Journal of Surgical Pathology

Select article: Zolbetuximab-clzb: Targeting Claudin 18.2 in Advanced Gastric and Gastroesophageal Adenocarcinoma

Retricted access

Review article

First published 2025-12

Zolbetuximab-clzb: Targeting Claudin 18.2 in Advanced Gastric and Gastroesophageal Adenocarcinoma

Gabrielle L. Gorwitz, David L. DeRemer

Annals of Pharmacotherapy

Select article: Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer

Open access

Research article

First published 2024

Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer

Zhening Zhang, Tong Xie, Yingxuan Wang [...]

Therapeutic Advances in Medical Oncology

Select article: Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative,proficient MMR,PD-L1 CPS ⩾1 metastatic gastric/gastroesophageal junction cancer

Open access

Research article

First published 2025

Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative,proficient MMR,PD-L1 CPS ⩾1 metastatic gastric/gastroesophageal junction cancer

Fei Zhang, Izuma Nakayama, Naoya Sakamoto [...]

Therapeutic Advances in Medical Oncology

Select article: Emerging targets in gastroesophageal adenocarcinoma: what the future looks like

Open access

Review article

First published 2023

Emerging targets in gastroesophageal adenocarcinoma: what the future looks like

Angelica Petrillo, Elizabeth C. Smyth, Hanneke W. M. van Laarhoven

Therapeutic Advances in Medical Oncology

Select article: Next-generation sequencing and biomarkers for gastric cancer: what is the future?

Open access

Review article

First published 2019

Next-generation sequencing and biomarkers for gastric cancer: what is the future?

Akihito Kawazoe, Kohei Shitara

Therapeutic Advances in Medical Oncology

Select article: Clinical and pathological analyses of gastric-type cervical adenocarcinoma and its prognostic relevance

Open access

Research article

First published 2025

Clinical and pathological analyses of gastric-type cervical adenocarcinoma and its prognostic relevance

Yun Xi, Fang Zhou, Yulan Liu [...]

Therapeutic Advances in Medical Oncology

Select article: Symptom Burden and Healthcare Resource Use in Patients With Claudin 18.2–Positive,HER2-Negative,Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Review

Open access

Research article

First published 2026

Symptom Burden and Healthcare Resource Use in Patients With Claudin 18.2–Positive,HER2-Negative,Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Review

Matheus Sewastjanow-Silva, Mok Oh, Lawrence Chang [...]

Clinical Medicine Insights: Oncology

Select article: Erratum to Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer

Free access

Correction

First published 2024

Erratum to Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer

Therapeutic Advances in Medical Oncology

Select article: The dawn of precision medicine in diffuse-type gastric cancer

Open access

Review article

First published 2022

The dawn of precision medicine in diffuse-type gastric cancer

Akira Ooki, Kensei Yamaguchi

Therapeutic Advances in Medical Oncology

1
2
10 / page

Article type

Publication date

Subjects

Access